-
The influx of innovative pharmaceutical companies has intensified, how to break the situation?
Time of Update: 2022-03-07
According to incomplete statistics, as of February 8, 2022, a total of 243 medical companies in the A-share market have released their 2021 performance forecasts, most of which are expected to increase, but there are also 60 companies that are pre-loss, accounting for about 25% .
-
Helping pharmaceutical companies to accelerate innovation, pharmaceutical machine companies will play a big role
Time of Update: 2022-03-07
Affected by this, the domestic pharmaceutical equipment industry will also better help the innovation and development of the pharmaceutical industry, and escort the quality and efficiency of its R&D and production .
-
After price correction, more than 300 drug regulations in the province were withdrawn from the Internet
Time of Update: 2022-03-07
In 2020, Liaoning Province also requires that the unselected drugs included in the scope of centralized drug procurement organized by the state implement a linked gradient price reduction .
-
In 2022, new changes are emerging in the financing of innovative pharmaceutical companies
Time of Update: 2022-03-07
Recently, many pharmaceutical companies have announced the completion of financing, which will be used for the research and development and promotion of new drugs .
-
6 multinational pharmaceutical companies announced their performance in China, which one performed better?
Time of Update: 2022-03-07
According to incomplete statistics, as of now, six multinational pharmaceutical companies including Roche, Novartis, Merck, Sanofi, AstraZeneca, and Eli Lilly have disclosed their performance in China while disclosing their 2021 financial reports .
-
Cefuroxime Sodium for Injection passed the consistency evaluation of generic drugs
Time of Update: 2022-03-07
(hereinafter referred to as the "Company"), received the "Supplementary Drug Application for Cefuroxime Sodium for Injection" approved and issued by the State Drug Administration.
Cefuroxime Sodium for Injection is Yifan Yosemite Pharmaceutical Technology Co.
jointly invested and established by the company's two wholly-owned subsidiaries, Zhejiang Jutai Pharmaceutical Co.
-
The environmental protection pressure of the pharmaceutical industry has intensified, and pharmaceutical companies need a diversified approach to energy conservation and emission reduction
Time of Update: 2022-03-07
It is worth mentioning that from the fourth quarter of 2020, with the improvement of national pollution control standards, Northeast Pharmaceuticals has invested another 340 million yuan on the basis of current environmental protection to carry out environmental protection improvements covering waste gas, wastewater and comprehensive utilization.
-
"Integration of Taoism and Devices" Helps China Biopharmaceuticals
Time of Update: 2022-03-07
There are literature data showing that increasing the single-pot culture volume to 15KL can reduce the unit production cost of antibody to about 40USD/g .
So what are the difficulties in designing and manufacturing large-scale bioreactors for cell culture?The answer is "process suitability", not tanks, piping, instrumentation, valves and control systems .
-
The performance of multinational pharmaceutical companies has generally recovered, and executives may usher in salary increases!
Time of Update: 2022-03-07
In addition to Roche and Novartis, Bristol-Myers Squibb, Sanofi, Merck, Eli Lilly and other multinational pharmaceutical companies have also achieved performance growth in 2021.
Although these pharmaceutical companies have not yet disclosed executive compensation Look, the total compensation of the CEOs of Johnson & Johnson, AbbVie, and Eli Lilly has exceeded 20 million US dollars .
-
New drug research and development is hot, focusing on these three directions!
Time of Update: 2022-03-07
In recent years, the research and development of ADC drugs has been hot, and the market scale has continued to expand.
In recent years, with the rapid increase in the research and development of new macromolecular drugs in China, the double-antibody track has attracted a number of companies to deploy.
-
Yinming Bio's new CAR-T product announces clinical data, HKP1 inhibitor is approved for clinical use
Time of Update: 2022-03-07
references:[1] Two new breakthroughs have been achieved in the research and development of HPK1 targets of Yinming Bio: the clinical data of cell therapy was announced at the EHA CAR-T conference, and the small molecule drug was approved for clinical use in China.
-
Ascletis Pharma Announces Submission of Marketing Authorization Applications for Ritonavir in Multiple European Countries
Time of Update: 2022-03-07
Other marketing authorization applications for ritonavir in European countries, North American countries and Asia-Pacific countries are also expected to be submitted in the near future .
-
Kexing Pharmaceutical's Human Erythropoietin Injection was awarded the "Approval Notice for Supplementary Drug Application"
Time of Update: 2022-03-07
On February 14, Kexing Pharmaceuticals announced that it received the “Approval Notice for Supplementary Drug Application” approved and issued by the State Food and Drug Administration on February 12.
-
In 2022, personnel adjustments in the pharmaceutical industry will still be frequent
Time of Update: 2022-03-07
Qian Guoshuang applied for his resignation as an independent director and member of the nomination committee of the ninth board of directors of the company due to personal reasons.
Chen Yong resigned from the above-mentioned positions, he still served as the deputy general manager of the company .
-
Focusing on the research and development of innovative drugs, domestic pharmaceutical companies will continue to set off a "financing wave"
Time of Update: 2022-03-07
This round of financing will be mainly used to further improve Yosano Bio's unique "ready-to-use" CAR-T The cell technology platform CBT-X20 is preparing for the Sino-US New Drug Clinical Trial (IND) application of the core product AT19 and the construction of the company's scientific research and production facilities .
-
The research and development of PD-(L)1 is becoming more and more popular, and pharmaceutical companies need to be cautious when entering the bureau
Time of Update: 2022-03-07
_ It is worth noting that the industry believes that while more and more PD-(L)1 products are brought to the market to bring more new treatment options to the majority of patients, the competition in this track will become more intense, and product price reductions will enter the "normal" category.
-
The growth rate of the centrifuge market exceeds 23%, and the biomedical industry is a major "support force" behind it
Time of Update: 2022-03-06
Some medical centrifuge manufacturers said that facing the future, the company will continue to increase investment in research and development, attach importance to innovation, continuously improve the stability and quality of domestic centrifuges, seize the opportunity of import substitution, and help the pharmaceutical and other industries to develop with higher quality .
-
Local pharmaceutical companies are accelerating overseas, but they still face many challenges
Time of Update: 2022-03-06
For example, in January 2021, BeiGene and Novartis reached a cooperation and licensing agreement on the development, production and commercialization of its self-developed PD-1 antibody drug tislelizumab in multiple countries, with a total transaction value of more than 2.
-
A large number of pharmaceutical companies will use acquisitions to accelerate the pace of innovation in the future
Time of Update: 2022-03-06
Of course, regarding CSPC's investment in the acquisition of a Biotech company, some insiders believe that this is actually a microcosm of how domestic traditional big pharmaceutical companies will accelerate the pace of innovation through acquisitions .
According to public information, Yongtai Bio is an innovative biotechnology company engaged in the research and development of cellular immunotherapy products.
-
Beilu Pharmaceutical's iopamidol injection passed the consistency evaluation of generic drugs
Time of Update: 2022-03-06
On February 16, Beilu Pharmaceutical announced that it had recently received the “Approval Notice for Supplementary Drug Application” (Notice No.
: 2022B00641, 2022B00642) issued by the State Drug Administration for two specifications of iopamidol injection.
Drugs pass the quality and efficacy consistency evaluation of generic drugs .
